Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female volunteers 18-60 years of age~Exclusion Criteria:~* Any auto-immune disease or other serious acute, chronic or progressive disease~* Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine~* History of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine~* Within the past 7 days, they have experienced any acute disease or infections requiring systemic antibiotic or antiviral therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- MF59 adjuvant H5N1 influenza vaccine 7.5 micrograms (Type: EXPERIMENTAL): None
- MF59 adjuvant H5N1 influenza vaccine 15 micrograms (Type: EXPERIMENTAL): None
- non-adjuvanted influenza vaccine 15 micrograms of H5N1 antigen (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).